Literature DB >> 9512187

Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma.

M Reiser1, C Bruns, P Hartmann, B Salzberger, V Diehl, G Fätkenheuer.   

Abstract

Raynaud's phenomenon is a common vascular side effect of chemotherapy drug regimens. Chemotherapy-induced Raynaud's phenomenon leading to acral gangrene has rarely been reported. In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. The literature is reviewed, and clinical symptoms, pathophysiology, and treatment options are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512187     DOI: 10.1007/bf01584368

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Digital gangrene following chemotherapy for AIDS-related Kaposi's sarcoma.

Authors:  R J Fertakos; D M Mintzer
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

2.  Cutaneous side-effects of bleomycin in AIDS patients with Kaposi's sarcoma.

Authors:  E Caumes; C Katlama; G Guermonprez; I Bournerias; M Danis; M Gentilini
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

3.  Protein S deficiency and HIV infection.

Authors:  A Lafeuillade; M C Alessi; I Poizot-Martin; C Dhiver; R Quilichini; L Aubert; J A Gastaut; I Juhan-Vague
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

4.  Digital gangrene, HIV infection and bleomycin treatment.

Authors:  M Vayssairat; J P Gaitz; N Bamberger
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

5.  Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold.

Authors:  S W Hansen; N Olsen
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

6.  Cutaneous toxicity of bleomycin therapy.

Authors:  I S Cohen; M B Mosher; E J O'Keefe; S N Klaus; R C De Conti
Journal:  Arch Dermatol       Date:  1973-04

Review 7.  Chemotherapy-induced Raynaud's phenomenon.

Authors:  E Toumbis-Ioannou; P R Cohen
Journal:  Cleve Clin J Med       Date:  1994 May-Jun       Impact factor: 2.321

8.  Bleomycin-induced scleroderma.

Authors:  W R Finch; G P Rodnan; R B Buckingham; R K Prince; A Winkelstein
Journal:  J Rheumatol       Date:  1980 Sep-Oct       Impact factor: 4.666

9.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.

Authors:  N J Vogelzang; G J Bosl; K Johnson; B J Kennedy
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

10.  Raynaud's phenomenon progressing to gangrene after vincristine and bleomycin therapy.

Authors:  I Elomaa; M Pajunen; P Virkkunen
Journal:  Acta Med Scand       Date:  1984
View more
  2 in total

Review 1.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

2.  Paraneoplastic Raynaud's phenomenon in a breast cancer survivor.

Authors:  David Allen; David Robinson; Shikha Mittoo
Journal:  Rheumatol Int       Date:  2009-06-11       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.